55 results about "Lipid lowering drug" patented technology

The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

The invention discloses mesoporous silica nanoparticles modified by nucleic acid aptamer targeting polyethylene glycol and a preparation method thereof. The method comprises the following steps: synthesizing mesoporous silica through TEOS(tetraethyl orthosilicate), CTAB(cetyltrimethyl ammonium bromide), alkali and water; modifying amino on the surface of the mesoporous silica through APTES (aminopropyltriethoxysilane) in an ethanol solution; and connecting the primary amine end group of the mesoporous silica to the carboxyl group of polyethylene glycol by reacting, connecting the terminal carboxyl group of a nucleic acid aptamer to the amine group of the polyethylene glycol on the mesoporous silica by reacting, and carrying, by the mesoporous silica nanoparticles, a lipid-lowering drug such as atorvastatin. The mesoporous silica nanoparticles and the preparation method thereof have the characteristics that the nucleic acid aptamer is bound with the biological target with high affinityand high specificity, the polyethylene glycol can improve the water dispersion and the sustained release capability of the carrier, and the mesoporous silica can carry hydrophilic and hydrophobic drugs of different molecular weights due to the characteristics of unique mesoporous structure, huge specific surface area, easy surface modification and the like.

The invention relates to a building method of a zebra fish hyperlipidemia model and application of the animal model to hyperlipidemia disease research and lipid-lowering drug screening. The building method of the zebra fish hyperlipidemia model mainly includes the steps of zebra fish selection, feeding of zebra fish by yolk powder, histochemical staining or fluorescent staining, image analysis and/or microwell plate analysis and statistical analysis. The building method has the advantages of simplicity, convenience, rapidity, economy, high efficiency, high throughput and the like, and the model can be used for hyperlipidemia disease research and lipid-lowering drug screening. The building method and application of the zebra fish bacterial infection model are of great significance to acceleration of research and development on lipid-lowering drugs and improvement on treatment of patients suffering from hyperlipidemia.

A concomitant agent to be used simultaneously or separately, comprising a combination of (a) 3-{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl}thiazolidine, a salt of the compound with an organic or inorganic and mono- or di-basic acid or a solvate thereof, and

(b) at least one kind of active ingredient selected from the group consisting of an active ingredient of a pharmaceutical agent selected from (i) an antidiabetic drug, (ii) a lipid lowering drug, (iii) an antihypertensive drug, (iv) a therapeutic drug for diabetic complications, (v) an antiobesity drug, (vi) an antiplatelet drug and (vii) an anticoagulant, a pharmaceutically acceptable salt thereof and a solvate thereof.

The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from β-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

Functional beverages and compositions are provided that suppress allergic rhinitis and prevent and treat hyperlipemia and related diseases thereof i.e. arteriosclerosis, obesity and liver diseases.

The O-methylated catechin expressed by the chemical formula (1) shown below is included in a constitutive effective amount as an allergic rhinitis-suppressing drug and a lipid-lowering drug;

[in which R1, R2, R3 and R4 are each independently a hydrogen atom or a methyl group, X1 and X2 are each independently a hydrogen atom or a hydroxy group.]

Provided are pharmaceutical compositions and methods for preventing or reducing niacin-induced flushing, where the pharmaceutical compositions comprise an aspirin component and a niacin component having different release profiles. Also provided are methods and compositions for preventing or reducing niacin-induced flushing, where the compositions comprise niacin, aspirin and a lipid-lowering drug other than niacin.

The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are expressed at intervals. The formulation of the present invention comprises statin-based lipid-lowering agent and dihydropyridine-based calcium channel blocker that affects cytochrome P450 enzyme as active ingredients, and is such constituted that the release rates of the aforementioned ingredients are different, thus preventing antagonism and side effects, while maintaining the synergistic effect, which leads to the convenience in medication.

The invention belongs to the technical field of extraction of a traditional Chinese medicine, and particularly relates to a method for extracting epiberberine and application thereof. The invention aims at solving the technical problem of providing new use of the epiberberine. The invention provides use of the epiberberine in preparation of a lipid-lowering drug. The invention also discloses use of the epiberberine in preparation of a drug for preventing or treating obesity. The invention also provides use of the epiberberine in preparation of an antioxidant drug. The invention also provides use of the epiberberine in preparation of a drug for preventing or treating atherosclerosis. The invention also provides an extraction method of the epiberberine. The method can be applied to preparation of the lipid-lowering drug, the antioxidant drug, the drug for preventing or treating atherosclerosis, the drug for preventing or treating obesity, and the like.

The invention discloses a liver-protecting kidney-strengthening detoxifying lipid lowering drug and a preparation method thereof, the liver-protecting kidney-strengthening detoxifying lipid lowering drug is composed of the following components by weight: 10-25% of mushrooms polysaccharide, 15-30% of coriolus versicolor polysaccharide, 15-30% of ganoderma lucidum polysaccharide, 10-25% of lycium barbarum polysaccharides, and 15-30% of red date polysaccharide. The mushrooms polysaccharide, coriolus versicolor polysaccharide, ganoderma lucidum polysaccharide, lycium barbarum polysaccharides and red date polysaccharide are processed into fine powder, proportionally mixed evenly, and processed by drying and sterilization into Chinese patent powder, the sterilized and evenly mixed Chinese patent powder is packed into a capsule tube instrument for sealing to obtain a capsule agent. The liver-protecting kidney-strengthening detoxifying lipid lowering drug has the advantages of simple process, fine and pure product, low cost, natural raw material plant, no any toxic and side effects, no addition of add any chemicals and excitants, people immune function can be enhanced, physical fitness can be improved, the liver-protecting kidney-strengthening detoxifying lipid lowering drug has the effects of protecting liver, strengthening kidney, lowering blood lipid and detoxifying, has remarkable medical and health care effects, ad can make people far away from sub-health.

A pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof, which is capable of treating or preventing side effects such as muscle toxicity caused by administering a statin-based lipid-lowering drug, and a pharmaceutical combination composition comprising a statin drug and a losartan drug as active ingredients are provided. The pharmaceutical composition comprising losartan or a pharmaceutically acceptable salt thereof provides an effect on treating or preventing muscle-related side effects caused by administration of a statin drug for treating hyperlipidemia, as well as an intrinsic pharmacological effect for treating or preventing hypertension. When administered along with a statin drug in sequence or co-administered at the same time with the statin drug, the pharmaceutical composition can exhibit an effect of effectively or significantly decreasing or preventing side effects such as muscle toxicity.

The present invention belongs to the technical field of drugs, and relates to a lipid-lowering drug ezetimibe compound. The lipid-lowering drug ezetimibe compound is measured by Cu-K alpha ray to obtain an X- ray powder diffraction pattern shown in Figure 1, the lipid-lowering drug ezetimibe compound has good liquidity, and a tablet prepared from the lipid-lowering drug ezetimibe compound has high dissolution, low impurity content, and good stability.

The invention discloses an application of asanicula astrantiifolia wolff extract in preparation of a blood fat reducing drug, which belong to the technical field of blood fat reducing medicines. The sanicula astrantiifolia wolff extract is one or more of a sanicula astrantiifolia wolff alcohol extract, a sanicula astrantiifolia wolff petroleum ether part and a sanicula astrantiifolia wolff ethyl acetate part; a preparation method of the sanicula astrantiifolia wolff alcohol extract comprises the following steps: crushing dry rhizomes of sanicula astrantiifolia wolff by adopting a crusher, sieving the material, adding a C1-C4 alcohol solution with the volume percentage of 20-100%, extracting the material for 0.5-2 hours, centrifuging, taking a supernate, carrying out rotary evaporation, andconcentrating the material to obtain the sanicula astrantiifolia wolff alcohol extract. Compared with the prior art, the sanicula astrantiifolia wolff alcohol extract provided by the invention has the properties of high safety and good lipid-lowering effect, and can be applied to medicines, foods or functional foods for preventing and adjunctively treating obesity, alcoholic fatty liver, non-alcoholic fatty liver, type 2 diabetes, metabolic syndrome, coronary heart disease and atherosclerotic diseases.